(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
06 October 2022 (06.10.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/213118 A1

(51) International Patent Classification:
C07K 7/64 (2006.01) *C12N 15/113* (2010.01)
C07K 19/00 (2006.01)

(21) International Application Number:
PCT/US2022/071489

(22) International Filing Date:
31 March 2022 (31.03.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/168,888	31 March 2021 (31.03.2021)	US
63/171,860	07 April 2021 (07.04.2021)	US
63/239,671	01 September 2021 (01.09.2021)	US
63/290,960	17 December 2021 (17.12.2021)	US
63/298,565	11 January 2022 (11.01.2022)	US
63/268,577	25 February 2022 (25.02.2022)	US

(71) Applicant: **ENTRADA THERAPEUTICS, INC.** [US/US]; 6 Tide Street, Boston, Massachusetts 02210 (US).

(72) Inventors; and

(71) Applicants: **DOUGHERTY, Patrick** [US/US]; 6 Tide Street, Boston, Massachusetts 02210 (US). **KHEIRABADI, Mahboubeh** [IR/US]; 6 Tide Street, Boston, Massachusetts 02210 (US). **LI, Xiang** [CN/US]; 6 Tide Street, Boston, Massachusetts 02210 (US). **QIAN, Ziqing** [CN/US]; 6 Tide Street, Boston, Massachusetts 02210 (US).

(74) Agent: **PERDOK, Monique M.** et al.; P.O. Box 2938, Minneapolis, Minnesota 55402 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

WO 2022/213118 A1

(54) Title: CYCLIC CELL PENETRATING PEPTIDES



FIG. 51

(57) Abstract: The present disclosure is directed to cell penetrating peptides, including cyclic cell penetrating peptides with high cytosolic delivery efficiency and reduced toxicity that are able to effectively deliver cargo inside a cell to treat a variety of conditions and diseases.

[Continued on next page]

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*